Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
Tango Therapeutics reported Q1 2026 financial results highlighting ongoing Phase 1/2 clinical trials of vopimetostat in combination with RAS(ON) inhibitors targeting pancreatic and lung cancers. The company holds a robust cash position of $380 million, providing runway into 2028, supports new leadership appointments to advance late-stage developmen…